ConductScience.org, home

Paper304590

Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.

Mathé G and 2 others. Recent Results Cancer Res, 1977. Cited by 17 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time. Papers, record 304590. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/304590

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.
PubMed
Journal
Recent Results Cancer Res
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.55
iCite
Revised in PubMed
2021-12-03
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mathé GG
2Halle-Pannenko OO
3Bourut CC

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CyclophosphamideMajor topic
ImmunityMajor topic
Leukemia L1210Major topic
Animals
Antilymphocyte Serum
Cell Survival
Immunosuppression Therapy
Mice
Mice, Inbred Strains
T-Lymphocytes

Source PubMed

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
8,422,664Effect of cisplatin upon expression of in vivo immune tumor resistance.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8422664PubMed
8,168,116Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.Cancer Immunol Immunother1994https://conductscience.org/library/papers/8168116PubMed
6,984,357Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge.Cancer Immunol Immunother1982https://conductscience.org/library/papers/6984357PubMed
6,553,510Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.Cancer Immunol Immunother1983https://conductscience.org/library/papers/6553510PubMed
3,933,817Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.Cancer Immunol Immunother1985https://conductscience.org/library/papers/3933817PubMed
3,677,124Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.Cancer Immunol Immunother1987https://conductscience.org/library/papers/3677124PubMed
3,584,212Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse.J Cancer Res Clin Oncol1987https://conductscience.org/library/papers/3584212PubMed
3,490,305Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.Cancer Immunol Immunother1986https://conductscience.org/library/papers/3490305PubMed
2,949,833In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.Cancer Immunol Immunother1987https://conductscience.org/library/papers/2949833PubMed
2,657,252Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.Med Oncol Tumor Pharmacother1989https://conductscience.org/library/papers/2657252PubMed
2,337,902Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.Cancer Immunol Immunother1990https://conductscience.org/library/papers/2337902PubMed
2,289,208Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.Cancer Immunol Immunother1990https://conductscience.org/library/papers/2289208PubMed
1,901,031Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.Cancer Immunol Immunother1991https://conductscience.org/library/papers/1901031PubMed
750,105Chemotherapy, a double agent in respect of immune functions.Cancer Chemother Pharmacol1978https://conductscience.org/library/papers/750105PubMed
535,129The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/535129PubMed
161,207Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/161207PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/304590

GET https://conductscience.org/api/papers/v1/304590/authors